At what enterprise value was MARLE GROUP acquired in 2009?

During the acquisition of MARLE GROUP by THE CARLYLE GROUP in 2009, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 50M - 150M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of MARLE GROUP when it was acquired by THE CARLYLE GROUP?

The estimated EV/EBITDA multiple for MARLE GROUP is in the range of 5x - 12x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was MARLE GROUP acquired by THE CARLYLE GROUP?

MARLE GROUP was acquired by THE CARLYLE GROUP in 2009.

What was the revenue of MARLE GROUP at the time of the deal?

The revenue of MARLE GROUP at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of MARLE GROUP during the acquisition?

MARLE GROUP's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the MARLE GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MARLE GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/marle-sancre-a-carlyle-119292

← DATABASE

Home Database Healthcare & PharmaMARLE GROUP

09/2009

MARLE GROUP acquired by THE CARLYLE GROUP

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics EV 50M - 150M EUR

Context

The Carlyle Group has acquired an 80% majority stake in Marle S.A. The company's President, Bernard Marle, along with his family, has reinvested to retain a 20% stake. This Primary LBO is designed to support the company's growth in a market expanding at 8% annually. The transaction structure includes a senior debt package co-arranged by CIC Est and LCL, as well as a vendor loan (credit-vendeur). Carlyle aims to professionalize the company and accelerate its international expansion.

MARLE GROUP, which reported an EBITDA margin of in 2009, is valued in this transaction at an EV/EBITDA multiple of , a level than the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Marle Group is a world-leading strategic partner and contract development and manufacturing organization (CDMO) dedicated exclusively to the orthopedic and traumatology industry. Headquartered in France, the company provides a complete, vertically integrated value chain—from initial R&D and design assistance to forging, casting, precision machining, specialized coating, and final sterile packaging. Its business model is built on high-precision industrial expertise, supporting global Original Equipment Manufacturers (OEMs) in the production of hip, knee, shoulder, and spine implants, as well as extremity and trauma devices. The organization operates several state-of-the-art production facilities across Europe and the United States, maintaining the most stringent international regulatory certifications (ISO 13485, FDA). Strategically, the firm acts as a mission-critical consolidator in the MedTech supply chain, benefiting from the structural growth in joint replacement surgeries driven by aging global populations and active lifestyles. Its value proposition is centered on "one-stop-shop" efficiency, technical mastery of biocompatible materials, and a commitment to accelerating the time-to-market for innovative surgical solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2009

2008

Other operations with MARLE GROUP

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2023	MARLE GROUP	NOWAK	FRANCE	Implants & Prosthetics
10/2019	DENTRESSANGLE	MARLE GROUP	FRANCE	Implants & Prosthetics
05/2016	IK PARTNERS	MARLE GROUP	FRANCE	Implants & Prosthetics

REFERENCES

Valuation range: EV 50M - 150M EUR

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MARLE GROUP by THE CARLYLE GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: marle group

Acquirer: the carlyle group